Trial Profile
A Phase II Study of the Addition of Opaganib to Androgen Antagonists in Patients With Prostate Cancer Progression on Enzalutamide or Abiraterone
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2024
Price :
$35
*
At a glance
- Drugs Opaganib (Primary) ; Abiraterone; Enzalutamide
- Indications Adenocarcinoma; Carcinoma; Ductal carcinoma; Prostate cancer
- Focus Therapeutic Use
- 31 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Mar 2024.
- 26 Sep 2023 Planned End Date changed from 30 Nov 2023 to 31 Dec 2023.
- 25 Jul 2023 Planned End Date changed from 30 Sep 2023 to 30 Nov 2023.